Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

C/EBPγ is dispensable for steady-state and emergency granulopoiesis.

Kardosova M, Zjablovskaja P, Danek P, Angelisova P, de Figueiredo-Pontes LL, Welner RS, Brdicka T, Lee S, Tenen DG, Alberich-Jorda M.

Haematologica. 2018 Aug;103(8):e331-e335. doi: 10.3324/haematol.2017.173781. Epub 2018 Mar 22. No abstract available.

2.

Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms.

Machado-Neto JA, Fenerich BA, Scopim-Ribeiro R, Eide CA, Coelho-Silva JL, Dechandt CRP, Fernandes JC, Rodrigues Alves APN, Scheucher PS, Simões BP, Alberici LC, de Figueiredo Pontes LL, Tognon CE, Druker BJ, Rego EM, Traina F.

Cell Death Dis. 2018 Feb 22;9(3):311. doi: 10.1038/s41419-017-0256-4.

3.

Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBPα expression.

Yong KJ, Basseres DS, Welner RS, Zhang WC, Yang H, Yan B, Alberich-Jorda M, Zhang J, de Figueiredo-Pontes LL, Battelli C, Hetherington CJ, Ye M, Zhang H, Maroni G, O'Brien K, Magli MC, Borczuk AC, Varticovski L, Kocher O, Zhang P, Moon YC, Sydorenko N, Cao L, Davis TW, Thakkar BM, Soo RA, Iwama A, Lim B, Halmos B, Neuberg D, Tenen DG, Levantini E.

Sci Transl Med. 2016 Aug 3;8(350):350ra104. doi: 10.1126/scitranslmed.aad6066.

PMID:
27488898
4.

Halofuginone inhibits phosphorylation of SMAD-2 reducing angiogenesis and leukemia burden in an acute promyelocytic leukemia mouse model.

Assis PA, De Figueiredo-Pontes LL, Lima AS, Leão V, Cândido LA, Pintão CT, Garcia AB, Saggioro FP, Panepucci RA, Chahud F, Nagler A, Falcão RP, Rego EM.

J Exp Clin Cancer Res. 2015 Jun 23;34:65. doi: 10.1186/s13046-015-0181-2.

5.

Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer.

de Figueiredo-Pontes LL, Wong DW, Tin VP, Chung LP, Yasuda H, Yamaguchi N, Nakayama S, Jänne PA, Wong MP, Kobayashi SS, Costa DB.

J Thorac Oncol. 2014 Feb;9(2):248-53. doi: 10.1097/JTO.0000000000000050.

6.

Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer.

Yamaguchi N, Lucena-Araujo AR, Nakayama S, de Figueiredo-Pontes LL, Gonzalez DA, Yasuda H, Kobayashi S, Costa DB.

Lung Cancer. 2014 Jan;83(1):37-43. doi: 10.1016/j.lungcan.2013.09.019. Epub 2013 Oct 14.

7.

DNMT1-interacting RNAs block gene-specific DNA methylation.

Di Ruscio A, Ebralidze AK, Benoukraf T, Amabile G, Goff LA, Terragni J, Figueroa ME, De Figueiredo Pontes LL, Alberich-Jorda M, Zhang P, Wu M, D'Alò F, Melnick A, Leone G, Ebralidze KK, Pradhan S, Rinn JL, Tenen DG.

Nature. 2013 Nov 21;503(7476):371-6. doi: 10.1038/nature12598. Epub 2013 Oct 9.

8.

Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.

Yasuda H, de Figueiredo-Pontes LL, Kobayashi S, Costa DB.

J Thorac Oncol. 2012 Jul;7(7):1086-90. doi: 10.1097/JTO.0b013e3182570919.

9.

Halofuginone has anti-proliferative effects in acute promyelocytic leukemia by modulating the transforming growth factor beta signaling pathway.

de Figueiredo-Pontes LL, Assis PA, Santana-Lemos BA, Jácomo RH, Lima AS, Garcia AB, Thomé CH, Araújo AG, Panepucci RA, Zago MA, Nagler A, Falcão RP, Rego EM.

PLoS One. 2011;6(10):e26713. doi: 10.1371/journal.pone.0026713. Epub 2011 Oct 28.

10.

Co-existence of t(6;13)(p21;q14.1) and trisomy 12 in chronic lymphocytic leukemia.

de Oliveira FM, de Figueiredo Pontes LL, Bassi SC, Dalmazzo LF, Falcão RP.

Med Oncol. 2012 Jun;29(2):1227-30. doi: 10.1007/s12032-011-9957-1. Epub 2011 Apr 29.

PMID:
21528409
11.

The effect of intravitreal ranibizumab on intraoperative bleeding during pars plana vitrectomy for diabetic traction retinal detachment.

Ribeiro JA, Messias A, de Almeida FP, Costa RA, Scott IU, de Figueiredo-Pontes LL, Jorge R.

Br J Ophthalmol. 2011 Sep;95(9):1337-9. doi: 10.1136/bjo.2010.195693. Epub 2011 Apr 27. No abstract available.

PMID:
21527416
12.

Identification of a new translocation that disrupts the RUNX1 gene in a patient with de novo acute myeloid leukemia.

Lucena-Araujo AR, de Figueiredo-Pontes LL, de Oliveira FM, de Lourdes Chauffaille M, Falcao RP, Rego EM.

Med Oncol. 2012 Jun;29(2):1114-8. doi: 10.1007/s12032-011-9890-3. Epub 2011 Mar 6.

PMID:
21380778
13.

Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study).

da R Lucena D, Ribeiro JA, Costa RA, Barbosa JC, Scott IU, de Figueiredo-Pontes LL, Jorge R.

Br J Ophthalmol. 2009 May;93(5):688-91. doi: 10.1136/bjo.2008.151233. Epub 2009 Feb 10.

PMID:
19208678
14.

Insertion (15;14)(q22;q13q32) in a case of Ph+ ALL.

de Oliveira FM, Falcão RP, de Figueiredo Pontes LL, Simões BP, Tone LG.

Cancer Genet Cytogenet. 2008 Aug;185(1):65-7. doi: 10.1016/j.cancergencyto.2008.05.005. No abstract available.

PMID:
18656700
15.

Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia.

de Figueiredo-Pontes LL, Pintão MC, Oliveira LC, Dalmazzo LF, Jácomo RH, Garcia AB, Falcão RP, Rego EM.

Cytometry B Clin Cytom. 2008 May;74(3):163-8. doi: 10.1002/cyto.b.20403.

16.

The co-expression of PML/RAR alpha and AML1/ETO fusion genes is associated with ATRA resistance.

Abreu e Lima RS, Baruffi MR, de Lima AS, de Oliveira FM, de Figueiredo-Pontes LL, Tone LG, Rogatto SR, Falcao RP, Ferrari Chauffaille Mde L, Rego EM.

Br J Haematol. 2005 Feb;128(3):407-9. No abstract available.

PMID:
15667548

Supplemental Content

Loading ...
Support Center